SUBSCRIBE
SUBSCRIBE
News   Deals

Bristol-Myers Squibb Company Announces Expiration of Hart-Scott-Rodino Review Period for Acquisition of Medarex, Inc.

August 12, 2009 | 
1 min read
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that the Hart-Scott-Rodino (HSR) review period for its tender offer for Medarex, Inc. (NASDAQ: MEDX) has expired.
Mergers & acquisitions
Bristol Myers Squibb Company
MORE ON THIS TOPIC
Large yellow signboard on metal frame with the word IPO. Clear sky in the background. Concept of share trading on stock market, capital investment, currency exchange
IPO
Peptide biotech Parabilis targets up to $476M IPO
June 4, 2026
 · 
2 min read
 · 
Gabrielle Masson
A handshake of businessmen. Modern design with a positive context. Concept of help, support, and agreement between businessmen. Modern art collage, trendy magazine style.
Deals
Regeneron deepens relationship with CytomX, adding up to $2B and eight targets
June 4, 2026
 · 
2 min read
 · 
Tristan Manalac
A train with blue background, 3d rendering. Computer digital drawing.
Artificial intelligence
Alnylam hops on AI train with up to $2B Inceptive partnership
June 4, 2026
 · 
1 min read
 · 
Tristan Manalac
Futuristic digital speedometer with glowing lines and red needle, representing fast acceleration and advanced automotive technology. vector eps10
Funding
NewLimit snags $435M after seeing age reversal in human liver cells
June 3, 2026
 · 
2 min read
 · 
Gabrielle Masson